CSF3 and neutropenia: The increased risk of neutropenia and FN with FOLFOXIRI/bevacizumab was independent of the analysed risk factors, but appeared more relevant among older patients and females, thus suggesting a more careful monitoring, but also to consider a primary G-CSF prophylaxis in selected cases when the triplet is chosen as the upfront regimen.